QGEN

Qiagen NV

QGEN.US qiagen.com + Research + Basket
CIK 0001015820
ISIN NL0015002SN0
CUSIP N72482123
Employees 5,500
Phone 31 77 355 6600
Fiscal year end December
IPO Jun 28, 1996
Address Hulsterweg 82, Venlo, Netherlands, 5912 PL
50.86
+0.03 (+0.06%)
USD · NYSE
52-week range
32.24
57.30
Trading at 74% of the 52-week range
Market Cap
10.50B
P/E Ratio
25.82
Forward P/E
15.75
Book Value
18.33
Div. Yield
0.00%
% Institutions
80.10%
% Insiders
0.481%

1 Year

+22.8%

3 Year

+43.8%

10 Year

+103.9%
Description

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Actions

Add an action for QGEN.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Roland Sackers CFO, MD & Member of Management Board 1968
Mr. Jonathan M. Pratt CEO & Member of Management Board 1970
Mr. Antonio Santos Senior VP & Head of Global Operations NA
Mr. Daniel Wendorff CEFA, CIIA VP & Head of Investor Relations NA
Mr. John Gilardi VP & Head of Corporate Communications NA
Ms. Stephany Foster Senior VP & Head of Human Resources 1979
Dr. Thomas Schweins Senior Vice President of Life Science Business Area NA
Dr. Thomas Theuringer Senior Director & Head of External Communications NA
Mr. Jean-Pascal Viola Senior VP & Head of Corporate Strategy and Business Development NA
Mr. Nitin Sood Senior VP & Head of Product Portfolio & Innovation 1973

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Wellington Management Company LLP 12.41M Jun 30, 2026 6.01% $0.08 -13.63%
T. Rowe Price Associates, Inc. 11.35M Jun 30, 2026 5.50% $0.04 34.70%
Principal Financial Group Inc 6.65M Jun 30, 2026 3.22% $0.13 120,281.69%
Vanguard Capital Management, LLC 6.21M Jun 30, 2026 3.01% $0.01 1.70%
BlackRock Inc 5.91M Jun 30, 2026 2.86% $0.00 12.48%
Morgan Stanley - Brokerage Accounts 5.04M Jun 30, 2026 2.44% $0.01 20.32%
Earnest Partners LLC 4.57M Jun 30, 2026 2.21% $0.64 18.22%
The Goldman Sachs Group Inc 4.44M Jun 30, 2026 2.15% $0.02 219.38%
NORGES BANK 4.33M Jun 30, 2026 2.09% $0.02 24.64%
Millennium Management LLC 3.85M Jun 30, 2026 1.86% $0.05 543.25%
Amundi 3.68M Jun 30, 2026 1.78% $0.03 -22.58%
Marshall Wace Asset Management Ltd 3.49M Jun 30, 2026 1.69% $0.11 341.96%
UBS Group AG 3.42M Jun 30, 2026 1.66% $0.02 139.39%
Helikon Investments Ltd 3.09M Jun 30, 2026 1.49% $3.60 70.64%
Bank of America Corp 3.00M Jun 30, 2026 1.45% $0.01 -7.68%
Dimensional Fund Advisors, Inc. 2.76M Jun 30, 2026 1.34% $0.02 65.57%
Fivespan Partners, LP 2.69M Jun 30, 2026 1.30% $24.78 0.00%
SEI Investments Co 2.35M Jun 30, 2026 1.14% $0.08 33.20%
Allspring Global Investments Holdings, LLC 2.22M Jun 30, 2026 1.08% $0.13 -10.34%
Deutsche Bank AG 2.19M Jun 30, 2026 1.06% $0.02 -60.98%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Health Care Inv 6.95M 3.36% ▲ 6.62% Sep 30, 2026
2 MFS International Equity R6 4.00M 1.94% ▼ 2.25% Sep 30, 2026
3 T. Rowe Price International Stock 3.04M 1.47% ▼ 7.44% Sep 30, 2026
4 Vanguard Total Intl Stock Index Inv 3.04M 1.47% ▼ 0.32% Sep 30, 2026
5 DekaFonds CF 2.55M 1.23% ▲ 50.91% Jun 30, 2026
6 MFS Research International I 2.47M 1.20% ▼ 2.24% Sep 30, 2026
7 Vanguard Developed Markets Index Admiral 2.01M 0.97% ▼ 0.04% Sep 30, 2026
8 Principal International Equity Inst 1.77M 0.86% ▲ 0.00% Sep 30, 2026
9 BlackRock Global Equity Mkt Netrl Instl 1.75M 0.85% ▲ 4.96% Jul 31, 2026
10 Folksam LO Världen 1.70M 0.83% ▲ 0.00% Sep 30, 2026

Financial Highlights

▼
Market Cap: $10.50B
EBITDA: $734.19M
P/E Ratio: $25.82
PEG Ratio: $1.36
Book Value: $18.33
Dividend/Share: $0.00
Dividend Yield: 0.00%
Earnings/Share: $1.97
Profit Margin: 19.49%
Operating Margin: 26.33%
ROA (TTM): 5.87%
ROE (TTM): 11.93%
Revenue (TTM): $2.10B
Revenue/Share (TTM): $10.16
Earnings Growth (YOY): 7.90%
Revenue Growth (YOY): 0.30%

Valuation Metrics

Enterprise Value: $11.35B
Trailing P/E: 25.82
Forward P/E: 15.75

Shares Statistics

Shares Outstanding: 206.50M
Shares Float: 205.17M
% Insiders: 0.481%
% Institutions: 80.10%
Shares Short: 7.20M
Shares Short (Prior Month): 7.66M
Short Ratio: 3.34
Short % Float: 3.95%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$2.09B
Cost of Goods Sold
adjust
$-798.50M
Gross Profit
subtotal
$1.29B
SG&A
adjust
$-125.68M
R&D
adjust
$-187.52M
Other Operating Expense
adjust
$-457.99M
Operating Income
subtotal
$520.31M
Other / Non-Operating Items
adjust
$-95.43M
Net Income
subtotal
$424.88M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about QGEN.US!